Cidara Therapeutics Announces Late-Breaking Presentation on CD388 at 10ᵗʰ ESWI Influenza Conference 2025

Core Insights - Cidara Therapeutics presented data on its influenza preventative candidate CD388 at the ESWI's 10th Influenza Conference, highlighting its potential as a single-dose treatment for influenza [1][2] Company Overview - Cidara Therapeutics is a biotechnology company utilizing its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, with CD388 as its lead candidate aimed at universal prevention of seasonal and pandemic influenza [4] Clinical Data - The translational efficacy data presented at the conference showed a strong correlation between preclinical findings and clinical outcomes from the Phase 2b NAVIGATE study, reinforcing confidence in CD388's effectiveness [2][3] - In preclinical studies, CD388 demonstrated potent activity against 12 seasonal and multiple pandemic influenza subtypes, with complete protection observed in mice receiving a single dose [3] - The Phase 2b NAVIGATE study indicated statistically significant prevention efficacy across all dose groups, with lower drug concentrations linked to higher infection rates [3] Regulatory Status - CD388 received Fast Track Designation from the FDA in June 2023, and the company announced positive top-line results from the Phase 2b NAVIGATE trial in June 2025, subsequently initiating the Phase 3 ANCHOR trial in September 2025 [4]